Stabilisation Notice

Catalent

21/02/2020 08:50

RNS Number : 7379D

J.P. Morgan Securities PLC.

21 February 2020

 

21 Feb 20

Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.

Catalent Pharma Solutions, Inc.

Post-stabilisation Period Announcement

Further to the pre-stabilisation period announcement 19 Feb 20, J.P. Morgan Securities plc, (contact: Emma Lovett 0207 134 2468) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014) or the rules of the Financial Conduct Authority) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.

Issuer:
Catalent Pharma Solutions, Inc.
Guarantor (if any):
N/A
Aggregate nominal amount:
EUR 825,000,000
Description:
EUR 8NC3 Senior Notes
Listing: Official List of the International Stock Exchange
Stabilisation Manager(s):
J.P. Morgan Securities plc (Stabilisation coordinator)
Barclays (Stabilisation Manager(s))
BofA (Stabilisation Manager(s))
RBC (Stabilisation Manager(s))
Deutsche Bank (Stabilisation Manager(s))
Mizuho (Stabilisation Manager(s))
UBS (Stabilisation Manager(s))
Offer price:
100

 

This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction

This announcement is not an offer of securities for sale into the United States. The securities referred to above have not been, and will not be, registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or an exemption from registration. There has not been and will not be a public offer of the securities in the United States

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

 

END

 

 

STAEAPAFALXEEEA